Synopsis Hydrocortisone plus Fludrocortisone therapy provides lower 90-day all-cause mortality in the adult with septic shock. The present study aims to test the hypothesis that hydrocortisone- plus-fludrocortisone therapy or drotrecogin alfa (activated) would improve the clinical outcomes of patients with septic shock. This week’s “MED FACT” discusses a clinical trial from The New England Journal of Medicine, “ Hydrocortisone plus Fludrocortisone for Adults with Septic Shock”. May 2018 Authors : D. Annane, A. Renault, C.
Brun ‑Buisson et. al. Key Takeaways: Hydrocortisone plus Fludrocortisone therapy provides lower 90-day all-cause mortality in the adult with septic shock. Objective: To test the hypothesis that hydrocortisone- plus-fludrocortisone therapy or drotrecogin alfa (activated) would improve the clinical outcomes of patients with septic shock. Study Type: Multicenter,…
